As the world continues to feel the impact of COVID-19, the biopharmaceutical industry is working around the clock to identify and develop safe and effective vaccines to prevent infection, while also researching and developing new ways to treat those infected with the virus.
To help advance potential treatments and vaccines for COVID-19 as quickly and safely as possible, America’s biopharmaceutical research companies have undertaken monumental efforts to accelerate the R&D process including clinical trials to establish the safety and efficacy of eventual treatments and vaccines. These efforts include the implementation of decentralized clinical trials, expansion of cross-sector partnerships and closer engagement with regulators. Companies are also working proactively and closer engagement with the U.S. Food and Drug Administration (FDA) and global regulators to help ensure the safety of trial participants, maintain compliance with good clinical practice through new and innovative approaches to clinical trials conduct and helping ensure the continuity of ongoing trials for other therapeutic areas during the COVID-19 public health emergency.
As we consider the long-term impacts COVID-19 could have on society, there are good reasons to hope that some of these changes to the ways we conduct R&D may become permanent improvements.